15 December 2020>: Clinical Research
Measurement of Cyclin D2 () Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma
Yu Qian 1ABCDEF , Jing-Wen Wang 1BC , Yu-Fang 1BCD , Xiao-Dong Yuan 1B , Yu-Chen Fan 12ADF , Shuai Gao 12CDFG , Kai Wang 12ADEG*DOI: 10.12659/MSM.927444
Med Sci Monit 2020; 26:e927444
Table 2 Association between CCND2 methylation status and clinical characteristics of HCC patients.
Parameter | CCND2 methylation in PBMCs | P-value | CCND2 methylation in plasma | P-value | ||
---|---|---|---|---|---|---|
Methylation, n (%) | No methylation, n (%) | Methylation, n (%) | No methylation, n (%) | |||
Age (years) | 0.802 | 0.524 | ||||
≤60 | 37 (47.44) | 41 (52.56) | 36 (46.15) | 42 (53.85) | ||
>60 | 18 (45.00) | 22 (55.00) | 16 (40.00) | 24 (60.00) | ||
Gender | 0.516 | 0.573 | ||||
Male | 39 (44.83) | 48 (55.17) | 37 (42.53) | 50 (57.47) | ||
Female | 16 (51.61) | 15 (48.39) | 15 (48.39) | 16 (51.61) | ||
HBeAg | 0.713 | 0.984 | ||||
Negative | 34 (45.33) | 41 (54.67) | 33 (44.00) | 42 (56.00) | ||
Positive | 21 (48.84) | 22 (51.16) | 19 (44.19) | 24 (55.81) | ||
Smoking | 0.703 | 0.563 | ||||
No | 26 (44.83) | 32 (55.17) | 24 (41.38) | 34 (58.62) | ||
Yes | 29 (48.33) | 31 (51.67) | 28 (46.67) | 32 (53.33) | ||
Alcohol | 0.795 | 0.717 | ||||
No | 31 (45.59) | 37 (54.41) | 29 (42.65) | 39 (57.35) | ||
Yes | 24 (48.00) | 26 (52.00) | 23 (46.00) | 27 (54.00) | ||
AFP (ng/mL) | 0.080 | 0.062 | ||||
≤20 | 28 (56.00) | 22 (44.00) | 27 (54.00) | 23 (46.00) | ||
>20 | 27 (39.71) | 41 (60.29) | 25 (36.76) | 43 (63.24) | ||
Tumor number | 0.851 | 0.573 | ||||
Single | 41 (47.13) | 46 (52.87) | 37 (42.53) | 50 (57.47) | ||
Multiple | 14 (45.16) | 17 (54.84) | 15 (48.39) | 16 (51.61) | ||
Vascular invasion | 0.012* | 0.008* | ||||
Negative | 24 (36.36) | 42 (63.64) | 22 (33.33) | 44 (66.67) | ||
Positive | 31 (59.62) | 21 (40.38) | 30 (57.69) | 22 (42.31) | ||
Tumor size | 0.992 | 0.751 | ||||
≤5 cm | 21 (46.67) | 24 (53.33) | 19 (42.22) | 26 (57.78) | ||
>5 cm | 34 (46.58) | 39 (53.42) | 33 (45.21) | 40 (54.79) | ||
Histological grading | 0.566 | 0.411 | ||||
Poor | 16 (44.44) | 20 (55.56) | 15 (41.67) | 21 (58.33) | ||
Moderate | 27 (44.26) | 34 (55.74) | 25 (40.98) | 36 (59.02) | ||
Well | 12 (57.14) | 9 (42.86) | 12 (57.14) | 9 (42.86) | ||
TNM staging | 0.004* | 0.001* | ||||
I/II | 26 (36.11) | 46 (63.89) | 23 (31.94) | 49 (68.06) | ||
III/IV | 29 (63.04) | 17 (36.96) | 29 (63.04) | 17 (36.96) | ||
CTP staging | 0.291 | 0.561 | ||||
A | 29 (41.43) | 41 (58.57) | 28 (40.00) | 42 (60.00) | ||
B | 23 (52.27) | 21 (47.73) | 22 (50.00) | 22 (50.00) | ||
C | 3 (75.00) | 1 (25.00) | 2 (50.00) | 2 (50.00) | ||
HBeAg – hepatitis B antigen; AFP – alpha-fetoprotein; TNM – tumor node metastasis; CTP – Child-Turcotte-Pugh; * significant difference ( |